

CLAIMS

1. Use of a CD24 protein in the manufacture of a medicament for treating or preventing Graft versus Host Disease (GVHD) in a subject who will undergo or has undergone a hematopoietic stem cell transplantation (HCT), wherein the CD24 protein is intended to be administered in three biweekly doses comprising a dose on the day before the HCT, a dose on day 14 after the HCT, and a dose on day 28 after the HCT.
2. The use of claim 1, wherein the use reduces the subject's risk of Grade III-IV acute GVHD.
3. Use of a CD24 protein in the manufacture of a medicament for treating or preventing mucositis in a subject.
4. The use of any one of claims 1-3, wherein the subject has a cancer.
5. The use of claim 4, wherein the cancer is Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Myelodysplastic syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML).
6. The use of claim 3, wherein the CD24 protein is administered at a dose of 240 mg or 480 mg.
7. The use of any one of claims 3 and 6, wherein the subject will undergo or has undergone a hematopoietic stem cell transplantation (HCT).
8. The use of claim 7, wherein the CD24 protein is to be administered before or after the HCT.
9. The use of claim 8, wherein the CD24 protein is to be administered one day before the HCT.
10. The use of claim 8 or 9, wherein the CD24 protein is to be administered more than once.
11. The use of claim 10, wherein the CD24 protein is to be administered in three biweekly doses, comprising a dose on the day before the HCT, a dose on day 14 after the HCT, and a dose on day 28 after the HCT
12. The use of claim 11, wherein the doses of the CD24 protein are 480 mg, 240 mg, and 240 mg, respectively.

13. The use of any one of claims 1-12, wherein the CD24 protein comprises a mature human CD24 polypeptide fused at its N-terminus or C-terminus to a Fc region of a mammalian immunoglobulin (Ig) protein.

14. The use of claim 13, wherein the mature human CD24 polypeptide comprises the sequence set forth in SEQ ID NO: 1 or 2.

15. The use of claim 14, wherein the Ig protein is human, and wherein the Fc region comprises a hinge region and CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, or IgA.

16. The use of claim 14, wherein the Ig protein is human, and wherein the Fc region comprises a hinge region and CH2, CH3 and CH4 domains of IgM.

17. The use of claim 15, wherein the CD24 protein comprises the sequence set forth in SEQ ID NO: 6, 11, or 12.

18. The use of claim 17, wherein the amino acid sequence of the CD24 protein consists of the sequence set forth in SEQ ID NO: 6, 11, or 12.

19. The use of any one of claims 1-18, wherein the CD24 protein is soluble.

20. The use of any one of claims 1-19, wherein the CD24 protein is glycosylated.

21. The use of any one of claims 1-20, wherein the CD24 protein is prepared using a eukaryotic expression system.

22. The use of claim 21, wherein the eukaryotic expression system comprises expression from a vector in mammalian cells.

23. The use of claim 22, wherein the mammalian cells are Chinese Hamster Ovary cells.